603 related articles for article (PubMed ID: 19936252)
1. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
Choi HY; Dieckmann M; Herz J; Niemeier A
PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
[TBL] [Abstract][Full Text] [Related]
2. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
[TBL] [Abstract][Full Text] [Related]
4. Competitive blocking of LRP4-sclerostin binding interface strongly promotes bone anabolic functions.
Katchkovsky S; Chatterjee B; Abramovitch-Dahan CV; Papo N; Levaot N
Cell Mol Life Sci; 2022 Jan; 79(2):113. PubMed ID: 35099616
[TBL] [Abstract][Full Text] [Related]
5. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
[TBL] [Abstract][Full Text] [Related]
6. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.
Balemans W; Piters E; Cleiren E; Ai M; Van Wesenbeeck L; Warman ML; Van Hul W
Calcif Tissue Int; 2008 Jun; 82(6):445-53. PubMed ID: 18521528
[TBL] [Abstract][Full Text] [Related]
7. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
[TBL] [Abstract][Full Text] [Related]
8. Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels.
Chang MK; Kramer I; Huber T; Kinzel B; Guth-Gundel S; Leupin O; Kneissel M
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):E5187-95. PubMed ID: 25404300
[TBL] [Abstract][Full Text] [Related]
9. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.
Lu W; Liu CC; Thottassery JV; Bu G; Li Y
Biochemistry; 2010 Jun; 49(22):4635-43. PubMed ID: 20446724
[TBL] [Abstract][Full Text] [Related]
10. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894
[TBL] [Abstract][Full Text] [Related]
11. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
[TBL] [Abstract][Full Text] [Related]
12. Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population.
Mencej-Bedrac S; Prezelj J; Kocjan T; Komadina R; Marc J
Calcif Tissue Int; 2009 Dec; 85(6):501-6. PubMed ID: 19898734
[TBL] [Abstract][Full Text] [Related]
13. Lrp4 expression by adipocytes and osteoblasts differentially impacts sclerostin's endocrine effects on body composition and glucose metabolism.
Kim SP; Da H; Li Z; Kushwaha P; Beil C; Mei L; Xiong WC; Wolfgang MJ; Clemens TL; Riddle RC
J Biol Chem; 2019 Apr; 294(17):6899-6911. PubMed ID: 30842262
[TBL] [Abstract][Full Text] [Related]
14. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function.
Leupin O; Piters E; Halleux C; Hu S; Kramer I; Morvan F; Bouwmeester T; Schirle M; Bueno-Lozano M; Fuentes FJ; Itin PH; Boudin E; de Freitas F; Jennes K; Brannetti B; Charara N; Ebersbach H; Geisse S; Lu CX; Bauer A; Van Hul W; Kneissel M
J Biol Chem; 2011 Jun; 286(22):19489-500. PubMed ID: 21471202
[TBL] [Abstract][Full Text] [Related]
15. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
[TBL] [Abstract][Full Text] [Related]
16. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.
Kamiya N; Kobayashi T; Mochida Y; Yu PB; Yamauchi M; Kronenberg HM; Mishina Y
J Bone Miner Res; 2010 Feb; 25(2):200-10. PubMed ID: 19874086
[TBL] [Abstract][Full Text] [Related]
17. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.
van Dinther M; Zhang J; Weidauer SE; Boschert V; Muth EM; Knappik A; de Gorter DJ; van Kasteren PB; Frisch C; Mueller TD; ten Dijke P
PLoS One; 2013; 8(4):e62295. PubMed ID: 23638027
[TBL] [Abstract][Full Text] [Related]
18. Wise regulates bone deposition through genetic interactions with Lrp5.
Ellies DL; Economou A; Viviano B; Rey JP; Paine-Saunders S; Krumlauf R; Saunders S
PLoS One; 2014; 9(5):e96257. PubMed ID: 24789067
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
[TBL] [Abstract][Full Text] [Related]
20. LRP4 association to bone properties and fracture and interaction with genes in the Wnt- and BMP signaling pathways.
Kumar J; Swanberg M; McGuigan F; Callreus M; Gerdhem P; Akesson K
Bone; 2011 Sep; 49(3):343-8. PubMed ID: 21645651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
